CVR number 42756962
Industry 72.1100 Research and experimental development on biotechnology

IMCOR ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  0.0% 0.0% 9.7% 17.5% 8.3%  
Credit score (0-100)  0 0 24 8 28  
Credit rating  N/A N/A BB B BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 3,250 1,226 1,253  
EBITDA  0.0 0.0 3,214 990 1,113  
EBIT  0.0 0.0 3,214 990 1,113  
Pre-tax profit (PTP)  0.0 0.0 3,220.0 957.2 1,175.0  
Net earnings  0.0 0.0 2,510.0 744.6 912.9  
Pre-tax profit without non-rec. items  0.0 0.0 3,220 957 1,175  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 2,436 3,180 3,975  
Interest-bearing liabilities  0.0 0.0 34.0 40.7 48.2  
Balance sheet total (assets)  0.0 0.0 3,308 3,481 4,139  
Net Debt  0.0 0.0 -1,280 -3,389 -3,948  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 3,250 1,226 1,253  
Gross profit growth  0.0% 0.0% 0.0% -62.3% 2.2%  
Employees  0 0 1 2 1  
Employee growth %  0.0% 0.0% 0.0% 100.0% -50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 3,308 3,481 4,139  
Balance sheet change%  0.0% 0.0% 0.0% 5.2% 18.9%  
Added value  0.0 0.0 3,214.0 990.1 1,112.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 98.9% 80.8% 88.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 97.5% 29.9% 31.1%  
ROI %  0.0% 0.0% 130.5% 35.7% 32.7%  
ROE %  0.0% 0.0% 103.0% 26.5% 25.5%  

Solidity 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  0.0% 0.0% 73.6% 91.3% 96.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -39.8% -342.2% -354.8%  
Gearing %  0.0% 0.0% 1.4% 1.3% 1.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 23.5% 154.9% 22.7%  

Liquidity 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.0 0.0 10.6 39.1 52.6  
Current Ratio  0.0 0.0 10.6 39.1 52.6  
Cash and cash equivalent  0.0 0.0 1,314.0 3,429.3 3,996.6  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 2,996.0 3,392.3 4,060.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 3,214 495 1,113  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 3,214 495 1,113  
EBIT / employee  0 0 3,214 495 1,113  
Net earnings / employee  0 0 2,510 372 913